JP2016511823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511823A5 JP2016511823A5 JP2015553864A JP2015553864A JP2016511823A5 JP 2016511823 A5 JP2016511823 A5 JP 2016511823A5 JP 2015553864 A JP2015553864 A JP 2015553864A JP 2015553864 A JP2015553864 A JP 2015553864A JP 2016511823 A5 JP2016511823 A5 JP 2016511823A5
- Authority
- JP
- Japan
- Prior art keywords
- kininogen
- intact
- value
- cut
- pkal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361754607P | 2013-01-20 | 2013-01-20 | |
| US61/754,607 | 2013-01-20 | ||
| PCT/US2014/012107 WO2014113712A1 (en) | 2013-01-20 | 2014-01-17 | Evaluation and treatment of bradykinin-mediated disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018221155A Division JP6772237B2 (ja) | 2013-01-20 | 2018-11-27 | ブラジキニン媒介障害の評価および治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511823A JP2016511823A (ja) | 2016-04-21 |
| JP2016511823A5 true JP2016511823A5 (https=) | 2017-02-23 |
| JP6444315B2 JP6444315B2 (ja) | 2018-12-26 |
Family
ID=51210106
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553864A Active JP6444315B2 (ja) | 2013-01-20 | 2014-01-17 | ブラジキニン媒介障害の評価および治療 |
| JP2018221155A Active JP6772237B2 (ja) | 2013-01-20 | 2018-11-27 | ブラジキニン媒介障害の評価および治療 |
| JP2020164435A Pending JP2021008483A (ja) | 2013-01-20 | 2020-09-30 | ブラジキニン媒介障害の評価および治療 |
| JP2022029441A Active JP7496380B2 (ja) | 2013-01-20 | 2022-02-28 | ブラジキニン媒介障害の評価および治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018221155A Active JP6772237B2 (ja) | 2013-01-20 | 2018-11-27 | ブラジキニン媒介障害の評価および治療 |
| JP2020164435A Pending JP2021008483A (ja) | 2013-01-20 | 2020-09-30 | ブラジキニン媒介障害の評価および治療 |
| JP2022029441A Active JP7496380B2 (ja) | 2013-01-20 | 2022-02-28 | ブラジキニン媒介障害の評価および治療 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11156612B2 (https=) |
| EP (3) | EP4234583A3 (https=) |
| JP (4) | JP6444315B2 (https=) |
| KR (3) | KR102381478B1 (https=) |
| CN (2) | CN105073778B (https=) |
| AU (4) | AU2014207420B2 (https=) |
| CA (2) | CA3209608A1 (https=) |
| CY (1) | CY1122164T1 (https=) |
| DK (1) | DK2948479T3 (https=) |
| ES (1) | ES2692408T3 (https=) |
| HR (1) | HRP20181734T1 (https=) |
| HU (1) | HUE041332T2 (https=) |
| IL (2) | IL273688B2 (https=) |
| LT (1) | LT2948479T (https=) |
| PL (1) | PL2948479T3 (https=) |
| PT (1) | PT2948479T (https=) |
| RS (1) | RS57890B1 (https=) |
| SI (1) | SI2948479T1 (https=) |
| SM (1) | SMT201800563T1 (https=) |
| TR (1) | TR201815856T4 (https=) |
| WO (1) | WO2014113712A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| KR102320178B1 (ko) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| EP4234583A3 (en) | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| AU2014240045A1 (en) | 2013-03-15 | 2015-09-10 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| CA2927695C (en) | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| WO2015061183A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| KR102607829B1 (ko) * | 2015-03-30 | 2023-12-01 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도 |
| EP4354146B1 (en) * | 2015-10-19 | 2026-04-15 | Takeda Pharmaceutical Company Limited | Immunoassay for the detection of cleaved high molecular weight kininogen |
| EP3387018A1 (en) | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| KR102874711B1 (ko) * | 2015-12-15 | 2025-10-23 | 다케다 파머수티컬 컴패니 리미티드 | 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법 |
| DK3464271T3 (da) | 2016-05-31 | 2020-06-15 | Kalvista Pharmaceuticals Ltd | Pyrazolderivater som plasma-kallikreininhibitorer |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| US11340237B2 (en) * | 2016-09-16 | 2022-05-24 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
| IL265195B2 (en) | 2016-09-16 | 2025-02-01 | Dyax Corp | Protein biomarkers for diseases related to the activation system |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| PT3716952T (pt) | 2017-11-29 | 2022-04-14 | Kalvista Pharmaceuticals Ltd | Formas de administração que incluem um inibidor de calicreína plasmática |
| WO2019165308A1 (en) * | 2018-02-22 | 2019-08-29 | The Regents Of The University Of California | Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| EP4090427A1 (en) | 2020-01-13 | 2022-11-23 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| US20230174674A1 (en) * | 2020-04-04 | 2023-06-08 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
| CN113777331A (zh) * | 2020-06-09 | 2021-12-10 | 张曼 | 尿液激肽原-1及其多肽片段在烧伤中的应用 |
| EP4548103A2 (en) * | 2022-06-30 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Protein biomarkers for lanadelumab treatment |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1312564C (en) | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
| US5047323A (en) | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
| US4908431A (en) * | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPS63185398A (ja) | 1986-09-10 | 1988-07-30 | Nippon Zoki Pharmaceut Co Ltd | 生理活性物質測定法 |
| US4882272A (en) | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
| US5025796A (en) | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1993003748A1 (en) * | 1991-08-13 | 1993-03-04 | Temple University - Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| WO1995021601A2 (en) | 1994-01-11 | 1995-08-17 | Protein Engineering Corporation | Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| JPH1084995A (ja) | 1996-09-12 | 1998-04-07 | Nippon Zoki Pharmaceut Co Ltd | 血液凝固第ｘｉｉ因子活性化法 |
| US5789261A (en) | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
| US6242210B1 (en) | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
| JP4346798B2 (ja) | 1999-08-19 | 2009-10-21 | 協和メデックス株式会社 | Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。 |
| US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| US7678541B2 (en) | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
| JP2002221519A (ja) | 2001-01-29 | 2002-08-09 | Sysmex Corp | 抗凝固剤およびそれを用いた抗凝固剤処理方法 |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| ES2348230T3 (es) | 2002-06-07 | 2010-12-01 | Dyax Corp. | Prevención y reducción de la isquemia. |
| WO2004005934A2 (en) * | 2002-07-04 | 2004-01-15 | Oxford Glycosciences (Uk) Ltd | Toxicity markers |
| US20070003552A1 (en) | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| PL1981519T3 (pl) * | 2005-12-29 | 2018-07-31 | Dyax Corp. | Hamowanie proteaz |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| US20090075887A1 (en) | 2007-08-21 | 2009-03-19 | Genzyme Corporation | Treatment with Kallikrein Inhibitors |
| US8263347B2 (en) * | 2007-10-18 | 2012-09-11 | Miyazaki Prefectural Industrial Support Foundation | Biomarker for diagnosis of liver disease |
| AU2008315938B2 (en) | 2007-10-22 | 2014-11-27 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| JP2012507723A (ja) | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| EP2369930A4 (en) | 2008-12-02 | 2012-10-03 | Joslin Diabetes Ct | METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS |
| AU2013205086A1 (en) * | 2009-01-06 | 2013-05-16 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| FR2942233B1 (fr) | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre |
| AU2010330743A1 (en) | 2009-12-18 | 2012-07-05 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| WO2012009447A2 (en) | 2010-07-13 | 2012-01-19 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| EP2645932B1 (en) | 2010-12-02 | 2016-03-02 | Becton, Dickinson and Company | Blood collection devices containing blood stabilization agent |
| KR102320178B1 (ko) * | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| WO2012170947A2 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| EP3320922A1 (en) | 2011-06-10 | 2018-05-16 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
| EP4234583A3 (en) | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| RU2015136025A (ru) | 2013-02-01 | 2017-03-06 | Бектон, Дикинсон энд Кампани | Устройства для сбора крови, содержащие добавки, ингибирующие контактный путь свертывания крови |
| WO2015061183A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| CA2927695C (en) * | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| EP4354146B1 (en) | 2015-10-19 | 2026-04-15 | Takeda Pharmaceutical Company Limited | Immunoassay for the detection of cleaved high molecular weight kininogen |
-
2014
- 2014-01-17 EP EP23164279.4A patent/EP4234583A3/en active Pending
- 2014-01-17 HU HUE14740444A patent/HUE041332T2/hu unknown
- 2014-01-17 SM SM20180563T patent/SMT201800563T1/it unknown
- 2014-01-17 DK DK14740444.6T patent/DK2948479T3/en active
- 2014-01-17 IL IL273688A patent/IL273688B2/en unknown
- 2014-01-17 TR TR2018/15856T patent/TR201815856T4/tr unknown
- 2014-01-17 PT PT14740444T patent/PT2948479T/pt unknown
- 2014-01-17 KR KR1020217000831A patent/KR102381478B1/ko active Active
- 2014-01-17 ES ES14740444.6T patent/ES2692408T3/es active Active
- 2014-01-17 CA CA3209608A patent/CA3209608A1/en active Pending
- 2014-01-17 CN CN201480005158.6A patent/CN105073778B/zh active Active
- 2014-01-17 US US14/761,690 patent/US11156612B2/en active Active
- 2014-01-17 KR KR1020227010217A patent/KR102523810B1/ko active Active
- 2014-01-17 KR KR1020157022389A patent/KR102203880B1/ko active Active
- 2014-01-17 EP EP14740444.6A patent/EP2948479B1/en active Active
- 2014-01-17 LT LTEP14740444.6T patent/LT2948479T/lt unknown
- 2014-01-17 EP EP18186356.4A patent/EP3456744B1/en active Active
- 2014-01-17 SI SI201430933T patent/SI2948479T1/sl unknown
- 2014-01-17 CA CA2897336A patent/CA2897336C/en active Active
- 2014-01-17 RS RS20181235A patent/RS57890B1/sr unknown
- 2014-01-17 AU AU2014207420A patent/AU2014207420B2/en active Active
- 2014-01-17 JP JP2015553864A patent/JP6444315B2/ja active Active
- 2014-01-17 PL PL14740444T patent/PL2948479T3/pl unknown
- 2014-01-17 WO PCT/US2014/012107 patent/WO2014113712A1/en not_active Ceased
- 2014-01-17 CN CN201911415224.8A patent/CN111044725B/zh active Active
- 2014-01-17 HR HRP20181734TT patent/HRP20181734T1/hr unknown
-
2015
- 2015-06-15 IL IL239428A patent/IL239428B/en active IP Right Grant
-
2018
- 2018-11-01 CY CY20181101140T patent/CY1122164T1/el unknown
- 2018-11-07 AU AU2018260845A patent/AU2018260845B2/en active Active
- 2018-11-27 JP JP2018221155A patent/JP6772237B2/ja active Active
-
2020
- 2020-09-30 JP JP2020164435A patent/JP2021008483A/ja active Pending
- 2020-11-25 AU AU2020277178A patent/AU2020277178B2/en active Active
-
2021
- 2021-10-01 US US17/491,813 patent/US20220170936A1/en active Pending
-
2022
- 2022-02-28 JP JP2022029441A patent/JP7496380B2/ja active Active
-
2024
- 2024-08-09 AU AU2024205664A patent/AU2024205664A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511823A5 (https=) | ||
| Nazy et al. | Platelet‐activating immune complexes identified in critically ill COVID‐19 patients suspected of heparin‐induced thrombocytopenia | |
| AU2018260845A1 (en) | Evaluation and treatment of bradykinin-mediated disorders | |
| JP2017524130A5 (https=) | ||
| JP2016536012A5 (https=) | ||
| JP2017500584A5 (https=) | ||
| JP2010516678A5 (https=) | ||
| JP2013500941A5 (https=) | ||
| JP2011177182A5 (https=) | ||
| Coskuner et al. | Adenosine triphosphate (ATP) reduces amyloid-β protein misfolding in vitro | |
| JP2017505897A5 (https=) | ||
| JP2015513370A5 (https=) | ||
| Jacquemin et al. | The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays | |
| JP2018523105A5 (https=) | ||
| CN103328501A (zh) | 新的生物标记及其在诊断、治疗孤独症中的用途 | |
| JP2014518377A5 (https=) | ||
| JP2019502095A5 (https=) | ||
| JP2020516289A5 (https=) | ||
| EA201490105A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| JP2015042652A5 (https=) | ||
| WO2008089135A3 (en) | Identification of biomarkers predictive of dasatinib effects in cancer cells | |
| Farjat-Pasos et al. | Transcatheter patent foramen ovale closure in stroke patients with thrombophilia: current status and future perspectives | |
| EA201491411A1 (ru) | Растворимый manf при поражениях бета-клеток поджелудочной железы | |
| WO2014153232A3 (en) | Methods and compositions for diagnosing preeclampsia | |
| BR112016021714A2 (pt) | imunoensaio e anticorpos para a detecção de cromogranina a |